#### SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

#### FORM 10-QSB

#### QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

|For the Quarterly Period Ended June 30, 2002 | Commission FileNumber 1-11700
|-------------------------------------------- | -----------------------------

---

|Delaware(State of Organization) |  |  | 04-2869857(I.R.S. Employer Number)
|------------------------------- |  |  | ----------------------------------

---

---

Check whether the issuer
(1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities and Exchange Act of 1934 during the preceding 12 months and (2) has
been subject to such filing requirements for the past 90 days.

As of June 30, 2002, the
issuer had 10,149,591 shares of Common Stock, $0.01 par value per share
outstanding.

`HEMAGEN DIAGNOSTICS, INC. AND SUBSIDIARIES

                                      INDEX

PART I.  FINANCIAL INFORMATION                                       PAGE NUMBER
                                                                     -----------

         Item 1. Financial Statements (unaudited)

                 Consolidated Balance Sheets;                                1
                 June 30, 2002 and
                 September 30, 2001

                 Consolidated Statements                                     3
                 Of Operations; three months and nine months
                 ended    June 30, 2002 and 2001

                 Consolidated Statements                                     4
                 Of Cash Flows; nine months
                 Ended June 30, 2002 and 2001

                 Notes to Consolidated                                       5
                 Financial Statements

         Item 2. Management's Discussion and                                 7
                 Analysis of Financial
                 Condition and Results of
                 Operations

         Item 3. Quantitative and Qualitative
                 Disclosures about Market Risk                              12

PART II.  OTHER INFORMATION

         Item 1.  Legal Proceedings                                         12
         Item 2.  Changes in Securities and Use of Proceeds                 12
         Item 5.  Other Information                                         12
         Item 6.  Exhibits and Reports on Form 8-K                          13












PART I  - Financial Information

Item 1.   Financial Statements
          --------------------

                   HEMAGEN DIAGNOSTICS, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)

                                                        June 30,   September 30,
                                                          2002        2001
                                                      -----------  -------------
ASSETS

Current Assets:
  Cash and cash equivalents                           $   378,475    $   672,378
  Accounts receivables, less allowance
    for doubtful accounts of $653,000
    and $645,000 at June 30, 2002 and
    September 30, 2001, respectively                    1,179,674      1,299,616
  Inventories                                           4,092,691      3,774,346
  Prepaid expenses and other current assets               163,921        113,226
                                                      -----------    -----------

          Total current assets                          5,814,761      5,859,566
                                                      -----------    -----------
Property and Equipment:
  Fixed assets                                          7,670,946      7,631,402
  Less accumulated depreciation                        (5,884,814)    (5,405,309)
                                                      -----------    -----------

                                                        1,786,132      2,226,093

Other assets                                              172,863        297,849
                                                      -----------    -----------

Total Assets                                          $ 7,773,756    $ 8,383,508
                                                      ===========    ===========


                 See Notes to Consolidated Financial Statements.



                                        1

                   Hemagen DIAGNOSTICS, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS

                                   (UNAUDITED)

LIABILITIES AND STOCKHOLDERS' EQUITY                  June 30,     September 30,
                                                       2002           2001
                                                   ------------    -------------
Current Liabilities:
  Current portion of subordinated note payable     $    173,027    $    136,256
  Accounts payable and accrued expenses               1,652,486       1,654,430
  Deferred Revenue                                      132,503         132,322
                                                   ------------    ------------
    Total Current Liabilities                         1,958,016       1,923,008
                                                   ============    ============

  Subordinated note payable                                --           145,070
  Senior subordinated secured convertible
    notes, net of Unamortized discount of
    $4,146,767 and $4,542,376 at June 30,
    2002 and September 30,2001, respectively          1,943,233       1,547,624
                                                   ------------    ------------

  Total liabilities                                   3,901,249       3,615,702
                                                   ------------    ------------

Stockholders' Equity

  Preferred stock, no par value - 1,000,000
    shares authorized; none issued                         --              --
  Common stock, $.01 par value - 30,000,000
    shares authorized; issued and outstanding:
    10,149,591 and 9,962,422 at June 30, 2002
    and September 30,2001, respectively                 101,494          99,624
  Additional paid-in capital                         20,919,703      20,693,054
  Accumulated deficit                               (16,967,406)    (15,853,966)
  Accumulative other comprehensive loss-
    foreign currency translation loss                   (91,647)        (81,269)
  Less treasury stock at cost; 100,000
     shares at June 30, 2002 and
     September 30, 2001, respectively                   (89,637)        (89,637)
                                                   ------------    ------------
  Total Stockholder's Equity                          3,872,507       4,767,806
                                                   ============    ============

  Total Liabilities and Stockholder's Equity       $  7,773,756    $  8,383,508
                                                   ============    ============



                 See Notes to Consolidated Financial Statements.

                                            2





                   HEMAGEN DIAGNOSTICS, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

                               Three Months Ended         Nine Months Ended
                            -------------------------  ------------------------
                              June 30,      June 30,    June 30,      June 30,
                                2002          2001        2002          2001
                            -----------   -----------  -----------  -----------
Revenues:

   Product sales             $2,359,847   $ 2,382,322   $7,177,363  $ 8,543,160

Costs and expenses:
   Cost of product sales      1,444,339     1,334,932    4,624,259    5,430,995
   Research and development     102,528        84,411      329,766      293,960
   Selling, general and
     administrative             828,388       830,134    2,548,815    2,681,493
                            -----------   -----------  -----------  -----------
Operating Income (loss)         (15,408)      132,845     (325,477)     136,712

Other expenses:
   Interest expense, net        281,580       197,138      777,724      576,769
   Other expenses                   962        76,916       10,241       92,040
                            -----------   -----------  -----------  -----------
Net loss before cumulative
  effect of a change in
  accounting principle         (297,950)     (141,209)  (1,113,442)    (532,097)
                            -----------   -----------  -----------  -----------
Cumulative effect of a
  change in accounting
  principle                        --            --           --     (1,130,384)
                            -----------   -----------  -----------  -----------

Net loss                     $ (297,950)  $  (141,209) $(1,113,442) $(1,662,481)
                            ===========   ===========  ===========  ===========
Net Loss per share -
  basic and diluted:
    Loss from continuing
    operations              $     (0.03)  $     (0.01) $     (0.11) $     (0.05)
    Cumulative effect
     of a change in
     accounting principle   $       --    $       --   $       --   $     (0.12)
                            -----------   -----------  -----------  -----------
                            $     (0.03)  $     (0.01) $     (0.11) $     (0.17)
                            ===========   ===========  ===========  ===========
Weighted average shares
  used in the calculation
  of loss per share
  basic and diluted          10,044,457     9,807,662    9,967,569    9,715,162
                            ===========   ===========  ===========  ===========


                 See Notes to Consolidated Financial Statements.

                                        3





                   HEMAGEN DIAGNOSTICS, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (UNAUDITED)

                                                          Nine Months Ended
                                                              June 30,
                                                     ---------------------------
                                                          2002          2001
                                                     ------------   ------------
Cash flows from operating activities:
  Net loss                                           $(1,113,442)   $(1,662,481)
  Adjustments to reconcile
    net loss to net cash provided
    by operating activities:
    Depreciation and amortization                        555,038        663,456
    Amortization of debt discount                        395,609        233,338
    Cumulative effect of a change in
      accounting principle                                  --        1,130,384
    Loss on sale of property and equipment                 1,459         13,175
  Changes in operating assets and liabilities:
    Accounts and other receivables                       176,860        472,364
    Prepaid expenses and other current assets            (36,695)        44,090
    Inventories                                         (318,345)       (69,894)
    Accounts payable and accrued expenses                218,466       (322,300)
    Deferred revenue                                         181           (587)
    Customer deposits                                       --          (81,239)
                                                      -----------    -----------

      Net cash (used in) provided
        by operating activities                         (120,869)       420,306
                                                      -----------    -----------

Cash flows from investing activities:
  Purchase of property and equipment                     (62,660)       (27,147)
  Proceeds from sale of property and equipment               192        151,374
                                                      -----------    -----------

      Net cash used in investing activities              (62,468)       124,227
                                                      -----------    -----------

Cash flows from financing activities:
  Repayments of subordinated note payable               (108,259)      (894,041)
  Exercise of stock options                                8,071           --
                                                      -----------    -----------

       Net cash used in financing activities            (100,188)      (894,041)
                                                      -----------    -----------

Effects of foreign exchange rate                         (10,378)          --
                                                      -----------    -----------

       Net decrease in cash and cash equivalents        (293,903)      (349,508)

Cash and cash equivalents at beginning of period         672,378      1,460,446
                                                      -----------    -----------

Cash and cash equivalents at end of
period                                               $   378,475    $ 1,110,938
                                                     ===========    ===========

Supplemental disclosure of cash
  flow information:
  Stock issued in satisfaction
  of consulting loan
  restructuring and director's
  fees                                               $   228,521    $   192,048
                                                     ===========    ===========

   Interest paid                                     $   376,301    $   393,289
                                                     ===========    ===========

                 See Notes to Consolidated Financial Statements.

                                        4`

HEMAGEN DIAGNOSTICS, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE A - BASIS OF PRESENTATION

The Company has prepared
the accompanying unaudited consolidated financial statements pursuant to the
rules and regulations of the Securities and Exchange Commission. These financial
statements should be read together with the financial statements and notes in
the Companys 2001 Annual Report on Form 10-KSB filed with the Securities
and Exchange Commission. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted. The accompanying condensed
consolidated financial statements reflect all adjustments and disclosures which,
in our opinion, are necessary for fair presentation. All such adjustments are of
a normal recurring nature. The results of operations for the interim periods are
not necessarily indicative of the results of the entire year.

#### NOTE B- NET
INCOME (LOSS) PER SHARE

Basic earnings per common
share are computed based upon the weighted average number of common shares
outstanding during the three and nine months ended June 30, 2002 and June 30,
2001. Diluted earnings per common share are computed based on common shares
outstanding plus the effect of dilutive stock options and other potentially
dilutive common stock equivalents consisting of stock purchase warrants and
convertible debentures. The dilutive effect of stock options and other
potentially dilutive common stock equivalents is determined using the treasury
stock and if-converted method based on the Companys average stock price.
Common stock equivalents totaling 8,566,910 and 10,769,215 at June 30, 2002 and
June 30, 2001, respectively, were not included in the computation of diluted net
loss per share because to do so would have been anti-dilutive.

#### NOTE C -
SHAREHOLDERS EQUITY

During the nine months
ended June 30, 2002, the Company granted options for the purchase of 421,500
shares of Common Stock to employees at exercise prices varying between $0.78 to
$1.15 per share, which represented the fair market value on the date of the
grant. Also, during the nine months ended June 30, 2002, options for the
purchase of 65,250 shares of Common Stock expired and options for the purchase
of 13,000 shares of common stock with an exercise price of $0.62 were exercised.
At June 30, 2002, options for the purchase of 2,920,110 shares of common stock
with a

5

weighted average exercise
price of $1.24 were outstanding. The Company issued an additional 174,169 shares
of common stock in lieu of cash payments, of which 120,948 shares of common stock
for consulting services recorded and previously accrued at $174,950 and 53,221 shares
of common stock were for directors compensation
with a value of $45,498.  On April 30, 2002, 2,595,755 warrants at an
exercise price of $2.75 expired.

#### NOTE D -
CONTINGENCIES

On February 7, 2002, URRMA
Biopharma, Inc. filed suit against the Company in the Superior Court, District
of Montreal, Providence of Quebec, Canada. The suit seeks $32,000,000 Cdn for an
alleged breach of contract for failure to provide information called for under
an alleged manufacturing agreement and for publishing misleading information
regarding the product. The Company had an understanding with URRMA Biopharma to
manufacture R7V diagnostic test kits and was in the process of negotiating a
comprehensive supply agreement. The Company responded to the claim and filed a
counter claim for $30,614,730 Cdn on June 10, 2002. Management is unable to
predict at this time the final outcome of the URRMA suit or whether the
resolution of the matter could materially affect the Companys results of
operations, cash flows or financial position.

6

MANAGEMENT'S DISCUSSION AND ANALYSIS
            OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements in this
report that are not historical facts constitute forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act of 1995, are
intended to be covered by the safe harbors created by that Act. Reliance should
not be placed on forward looking statements because they involve unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to differ materially from those expressed or implied. Any
forward-looking statement speaks only as of the date made. The Company
undertakes no obligation to update any forward-looking statements to reflect
events or circumstances after the date on which they are made.

Statements concerning the
establishments of reserves and adjustments for dated and obsolete products,
relocation expenses, expected financial performance, on-going business
strategies and possible future action which Hemagen intends to pursue to achieve
strategic objectives constitute forward-looking information. The sufficiency of
such charges, implementation of strategies and the achievement of financial
performance are each subject to numerous conditions, uncertainties and risk
factors. Factors which could cause actual performance to differ materially from
these forward-looking statements, include, without limitation, managements
analysis of Hemagens assets, liabilities and operations, the failure to
sell datesensitive inventory prior to its expiration, the inability of
particular products to support goodwill allocated to them, competition, new
product development by competitors which could render particular products
obsolete, the inability to develop or acquire and successfully introduce new
products or improvements of existing products, costs and difficulties in
complying with laws and regulations administered by the U.S. Food and Drug
Administration and the ability to assimilate successfully product acquisitions.

#### Overview

Hemagen Diagnostics, Inc.
is a biotechnology company, which develops, manufactures, and markets more than
150 FDA-cleared proprietary medical diagnostic test kits used to aid in the
diagnosis of certain autoimmune and infectious diseases. In the United States,
the Company sells its products directly to physicians, veterinarians, clinical
laboratories and blood banks. Internationally, the Company sells its products
primarily through distributors. Hemagen also manufactures and sells the Analyst
an FDA-cleared clinical chemistry analyzer used to measure important
constituents in human and animal blood and the Endochek a clinical chemistry
analyzer used to measure important constituents in animal blood. The Company
sells the Analyst both directly and through distributors servicing both the
physicians office laboratories and veterinarians offices while the
Endochek is sold only to veterinarians offices. The Company focuses on
markets that offer significant growth opportunities. The Company was
incorporated in 1985 and went public in 1993.

7

#### Results of
Operations

The Three Month Period Ended June 30, 2002
Compared to the Three Month Period Ended June 30, 2001

Revenues for the three month
period ending June 30, 2002 decreased $22,000 (1%) to approximately $2,360,000
from approximately $2,382,000 for the same period ending June 30, 2001. Sales
for the current period represent reduced sales at the Companys Raichem
division offset by sales of the Endochek product line that was purchased in
December 2001.

Cost of product sales
increased eight percent (8%) to approximately $1,444,000 from approximately
$1,335,000 in the same period last year despite the slight decrease in sales for
the applicable period. Cost of product sales as a percentage of sales increased
from 56% to 61%. This increase of cost of sales mainly resulted from higher
costs associated with the Analyst product line and costs at the Raichem division
as a result of lower production efficiencies.

Research and development
expenses increased twenty-two percent (22%) to approximately $103,000 from
approximately $84,000, due to the timing of expenditures, and temporary labor
being used at the Raichem division.

The Company is currently
working to complete several research and development programs including:

- The completion of clinical
trials and the submission of applications to the FDA to market new blood banking
products.
- The continuation of
the development of additional assays and reagents to fill its clinical chemistry
reagent product line sold under the RAICHEM label.

Other expenses increased to
approximately $283,000 in the quarter ended June 30, 2002 from approximately
$274,000 (3%) in the prior period, attributed to increased interest expense.
Interest expense for the three months ended June 30, 2002, was $282,000 as
compared to $197,000 in the three months ended June 30, 2001, the increase in
interest expense resulted from the amortization of the Senior Subordinated
Convertible Notes. (See Liquidity and Capital Resources).

8

The net loss for the period
was approximately $298,000 for the three months ended June 30, 2002 as compared
to a net loss of approximately $141,000 in the prior period. The increase in the
net loss from the prior period resulted from lower sales and gross margin in the
current quarter.

The Nine Month Period Ended June 30, 2002
Compared to the Nine Month Period Ended June 30, 2001

Revenues for the nine month
period ending June 30, 2002 decreased to approximately $7,177,000 from
approximately $8,543,000 (16%) for the same period ending June 30, 2001. This
decrease is attributed to:

- Reduced sales of approximately $640,000 at the Companys Raichem division.
This reduction was a result of initial stocking orders of approximately $400,000
for certain products in the Roche Diagnostics supply agreement that were shipped
in the prior year. Also, one substantial annual customer order of approximately
$150,000 that was produced in the prior period, has not been received in the current
period, and a decrease in sales to Raichems foreign distributors.
- Prior year sales included approximately $435,000 of inventory sell-off
associated with the February 2001 termination of a contract manufacturing
agreement with Carter Wallace.
- Reduced sales of the Companys autoimmune and infectious disease product
line, including the Companys Brazilian operations, of approximately
$275,000.

Cost of product sales decreased to approximately $4,624,000 from approximately
$5,431,000 (15%). As a
percentage of sales, cost of product sales remained 64% of sales as compared to
the same period last year.

Research and development
expenses increased to $330,000 from $294,000 (12%) as a result of additional
consulting and project expenditures in the current period. For a detail of
current research and development projects see the comparison of three month
periods ended June 30, 2002 and 2001.

Selling, general and
administrative expenses decreased to approximately $2,549,000 from approximately
$2,681,000 (5%), due to reduced administrative expenses in fiscal 2002.

Other expenses increased to
approximately $788,000 from approximately $669,000 (18%) during the same period
last year. The increase is a result of higher interest expense associated with
the amortization of the Senior Subordinated Convertible Notes. (See
Liquidity and Capital Resources).

9

Net loss before the
cumulative effect of a change in accounting principle for the nine months ended
June 30, 2002 was $1,113,000 as compared to approximately $532,000 in the same
period last year. This reduction is attributed to a decrease in the sales volume
and gross margins and the increase in interest expense.

In the first quarter of
2001, the Company recorded a cumulative effect of a change in accounting
principle that resulted in a one-time non-cash charge of $1,130,000. The change
in accounting principle was recognized as a result of a new accounting
pronouncement regarding the accounting for the Senior Subordinated Secured
Convertible Notes issued in conjunction with the private placement offering
completed in May 2000.

#### Liquidity and
Capital Resources

At June 30, 2002, the
Company had $378,000 of unrestricted cash, working capital of $3,857,000 and a
current ratio of 3.0 to 1.

During the period ended
June 30, 2002, Hemagen used $121,000 of cash for operating activities, $62,000
on capital expenditures and $100,000 for financing activities. Capital
expenditures of approximately $15,000 are planned for remainder of fiscal 2002.

Hemagen believes that cash
flow from operations and cash on hand at June 30, 2002 will be sufficient to
finance its operations and capital expenditures for fiscal 2002, but Hemagen can
give no assurance that it will have sufficient cash flow to finance operations
ongoing. Hemagen is attempting to secure a traditional working capital revolving
line of credit for up to $1 million. The Senior Secured Subordinated Convertible
Notes provide for Hemagen to secure such financing by allowing the lender to
obtain a first lien on all assets of Hemagen ahead of the Subordinated Note
holders in an amount not to exceed $1 million. Hemagen can give no assurance
that it will be able to obtain such financing or, if obtained, that such terms
will be favorable to the company.

The Nine Month Period Ended June 30, 2002 Compared to the Nine
Month Period Ended June 30, 2001

Cash used in operating
activities during the nine months ended June 30, 2002 was approximately $121,000
as compared to cash generated in the nine months ended June 30, 2001. This
decrease in cash generated is mainly attributed to the net loss from operations
after adjusting for non-cash items such as depreciation, amortization and the
cumulative effect of a change in accounting principle. The net loss after
adjusting for non-cash items for the nine months ended June 30, 2002 used cash
of approximately $161,000 as compared to $378,000 of cash generated in the
previous period.

10

Cash used in investing
activities totaled $62,000 in the nine months ended June 30, 2002 as compared to
cash generated of $124,000 in the nine months ended June 30, 2001. This increase
in cash used is attributed to capital expenditures in the current period as
compared to the disposal of assets in the prior period.

Cash used in financing
activities totaled $100,000 in the nine months ended June 30, 2002 as compared
to $894,000 used in the nine months ended June 30, 2001. This decrease in cash
used is attributed to the scheduled payments required for the subordinated note
payable to Dade Behring Inc. In the nine months ended June 30, 2001 a payment of
$800,000 was made to Dade Behring, Inc. to restructure the subordinated note
payable.

11

#### Item 3.   
Quantitative and Qualitative Disclosures About Market Risks

| | The
Company does not believe there is any major market risk exposure with respect to
derivative or other financial instruments that would require disclosure under
this item.
| | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PART II - Other Information

#### Item 1.    Legal
Proceedings for URRMA

| | On
February 7, 2002, URRMA Biopharma, Inc. filed suit against the Company in the
Superior Court, District of Montreal, Providence of Quebec, Canada. The suit
seeks $32,000,000 Cdn for an alleged breach of contract for failure to provide
information called for under an alleged manufacturing agreement and for
publishing misleading information regarding the product. The Company had an
understanding with URRMA Biopharma to manufacture R7V diagnostic test kits and
was in the process of negotiating a comprehensive supply agreement. The Company
responded to the claim and filed a counter suit for $30,614,730 Cdn on June 10,
2002. Management is unable to predict at this time the final outcome of the
URRMA suit or whether the resolution of the matter could materially affect the
Companys results of operations, cash flows or financial position.
| | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### Item 2.     Changes in Securities and Use of Proceeds.

|(c) | On February 13, 2002, the Registrant issued 115,948 shares of common stock to
two former directors Thomas A. Donelan and Christopher P. Hendy as consideration
for consulting services provided by the directors in fiscal year 2000. This
stock compensation was approved by the shareholders at the annual shareholders
meeting held on February 27, 2001. The issuance of the security was exempt from
registration from the Securities Act of 1933 pursuant to the exemption provided
by Section 4(2) of that Act.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### Item 5.     Other Information.

| | Hemagen's Annual Meeting of Shareholders was held on February 27, 2002.  Each
of the following matters was voted upon and approved by Hemagen's shareholders as
indicated below:

(1)   Election of the following two directors:
       Howard F. Curd        7,370,618 votes for,
128,630 votes against, and zero abstentions.
       William P. Hales        7,372,758 votes for,
126,490 votes against, and zero abstentions.
| | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

12

#### 

| | (2)   Ratification of appointment of Grant Thornton, LLP as Hemagen's
independent public        
accountants for fiscal  year 2003, 7,469,941 votes
for, 15,532 votes against, and        13,775 abstentions
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### Item 6.     Exhibits and Reports on Form 8-K.

| | Exhibit 99.1   Certification of Chief Executive Officer
Exhibit 99.2   Certification of Chief Financial Officer
| | ---------------------------------------------------------------------------------------------------------------

13

#### SIGNATURES

Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf of the undersigned thereunto duly
authorized.

|August 14, 2002August 14, 2002 | Hemagen Diagnostics, Inc.
                                                     (Registrant)/s/William P. HalesWilliam P. Hales
President &Chief Executive Officer/s/Deborah F. RicciDeborah F. Ricci
 Chief Financial Officer
|------------------------------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------